Short- and long-term mechanical ventricular assistance towards myocardial recovery

Entwistle, John W.

doi:10.1016/s0039-6109(03)00213-5

Cited by 20 publications

(8 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[1][2][3][4][5] However, assessment of myocardial recovery depends critically on a safe, accurate and reproducible method of monitoring myocardial function during the period of LVAD support. We have previously described our experience with recovery assessment in patients with the pulsatile-flow HeartMate I (HMI) LVAD (Thoratec Corp., Pleasanton, CA), where acute device cessation was safe and efficient in assessing the contractile reserve and the underlying function of the native myocardium.…”

mentioning

confidence: 99%

Echocardiographic assessment of flow across continuous-flow ventricular assist devices at low speeds

George

Sabharwal

Webb

et al. 2010

The Journal of Heart and Lung Transplantation

View full text Add to dashboard Cite

mentioning

confidence: 99%

Echocardiographic assessment of flow across continuous-flow ventricular assist devices at low speeds

George

Sabharwal

Webb

et al. 2010

The Journal of Heart and Lung Transplantation

View full text Add to dashboard Cite

“…Serendipitously, the clinical experience with LVADs has suggested that the use of LVADs not only has become a reliable means of sustaining medically refractory patients with heart failure awaiting cardiac transplantation, but also implicated the potential as a bridge to recovery (Bick et al, 2005; Dandel et al, 2005; Entwistle, 2004; Wohlschlaeger et al, 2005; Zhang & Narula, 2004). An early report in 1994 documented the improvement of cardiac parameters in a transplant candidate living in a hospital with the support of a LVAD (Frazier, 1994).…”

Section: Left Ventricular Assist Devices (Lvads) In the Regressionmentioning

confidence: 99%

Regression of pathological cardiac hypertrophy: Signaling pathways and therapeutic targets

Hou

Kang

2012

Pharmacology & Therapeutics

View full text Add to dashboard Cite

Pathological cardiac hypertrophy is a key risk factor for heart failure. It is associated with increased interstitial fibrosis, cell death and cardiac dysfunction. The progression of pathological cardiac hypertrophy has long been considered as irreversible. However, recent clinical observations and experimental studies have produced evidence showing the reversal of pathological cardiac hypertrophy. Left ventricle assist devices used in heart failure patients for bridging to transplantation not only improve peripheral circulation but also often cause reverse remodeling of the geometry and recovery of the function of the heart. Dietary supplementation with physiologically relevant levels of copper can reverse pathological cardiac hypertrophy in mice. Angiogenesis is essential and vascular endothelial growth factor (VEGF) is a constitutive factor for the regression. The action of VEGF is mediated by VEGF receptor-1, whose activation is linked to cyclic GMP-dependent protein kinase-1 (PKG-1) signaling pathways, and inhibition of cyclic GMP degradation leads to regression of pathological cardiac hypertrophy. Most of these pathways are regulated by hypoxia-inducible factor. Potential therapeutic targets for promoting the regression include: promotion of angiogenesis, selective enhancement of VEGF receptor-1 signaling pathways, stimulation of PKG-1 pathways, and sustention of hypoxia-inducible factor transcriptional activity. More exciting insights into the regression of pathological cardiac hypertrophy are emerging. The time of translating the concept of regression of pathological cardiac hypertrophy to clinical practice is coming.

show abstract

“…A majority of HF subjects had poor myocardial function for a number of years prior to LVAD placement [2]. Also during this time, numerous drugs were used to combat the progression of HF [39].…”

Section: Oxidative Stressmentioning

confidence: 99%

Effects of Left Ventricular Assist Device (LVAD) Placement on Myocardial Oxidative Stress Markers

Templeton

Mosser

Chen

et al. 2012

Heart, Lung and Circulation

View full text Add to dashboard Cite

Short- and long-term mechanical ventricular assistance towards myocardial recovery

Cited by 20 publications

References 23 publications

Echocardiographic assessment of flow across continuous-flow ventricular assist devices at low speeds

Echocardiographic assessment of flow across continuous-flow ventricular assist devices at low speeds

Regression of pathological cardiac hypertrophy: Signaling pathways and therapeutic targets

Effects of Left Ventricular Assist Device (LVAD) Placement on Myocardial Oxidative Stress Markers

Contact Info

Product

Resources

About